NCT06532370 Implementing a Contingency Management Program Addressing Methamphetamine Use For and With the People of Hawaii
| NCT ID | NCT06532370 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Queen's Medical Center |
| Condition | Contingency Managment |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-10-10 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-10-10 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to use contingency management (CM) as an intervention tool to address methamphetamine use. The main objectives are to: * Gather effectiveness data on a pilot a CM program for participants in Hawaii who use methamphetamine following hospitalization due to traumatic injury * To assess participant perspectives on engaging with a CM program based at a Level 1 Trauma Center. Researches will assess both patient-reported and biologically-confirmed medium-term program effectiveness and conduct qualitative interviews with participants post-program. Participants will: * Visit a follow-up clinic up to three times per week to complete urinalysis following discharge from the trauma unit * Complete Treatment Effectiveness Assessments at 6 and 12-weeks * Engage in a qualitative interview at the end of the CM program
Eligibility Criteria
Inclusion Criteria: * Admitted trauma patients * Age greater than 18 years old * Urine drug screen positive for methamphetamines during the current hospitalization * Report at least weekly methamphetamine use * First methamphetamine use greater than 6 months prior to injury * Report at least 4 DSM-V Amphetamine-Type Substance Use Disorder symptoms (at least moderate disease) * Glasgow Coma Scale ≥13 upon arrival to the emergency department * Ability to understand and participate in study procedures * Ability to communicate in English Exclusion Criteria: * Active psychosis (reporting auditory or visual hallucinations) * Under ongoing cardiorespiratory monitoring * Evidence of moderate or severe traumatic brain injury * Patients who are known to be pregnant * Prisoner * Individuals incarcerated at the time of their hospitalization * Individuals lacking capacity to provide, or are otherwise unable or unwilling to provide written informed consent
Contact & Investigator
Todd Seto, MD
STUDY CHAIR
The Queens Medical Center
Frequently Asked Questions
Who can join the NCT06532370 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Contingency Managment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06532370 currently recruiting?
Yes, NCT06532370 is actively recruiting participants. Contact the research team at nschumann@queens.org for enrollment information.
Where is the NCT06532370 trial being conducted?
This trial is being conducted at Honolulu, United States.
Who is sponsoring the NCT06532370 clinical trial?
NCT06532370 is sponsored by Queen's Medical Center. The principal investigator is Todd Seto, MD at The Queens Medical Center. The trial plans to enroll 40 participants.